Multi-organ protection of ulinastatin in traumatic cardiac arrest model

Shaoyun Liu¹², Jiefeng Xu¹²,³, Yuzhi Gao¹,², Peng Shen¹,²,⁴, Senlin Xia¹,²,⁵, Zilong Li³ and Mao Zhang¹,²*

Abstract

Background: Post-cardiac arrest syndrome, which has no specific curative treatment, contributes to the high mortality rate of victims who suffer traumatic cardiac arrest (TCA) and initially can be resuscitated. In the present study, we investigated the potential of ulinastatin to mitigate multiple organ injury after resuscitation in a swine TCA model.

Methods: Twenty-one male pigs were subjected to hemodynamic shock (40% estimated blood loss in 20 min) followed by cardiac arrest (electrically induced ventricular fibrillation) and respiratory suspension for 5 min, and finally manual resuscitation. At 5 min after resuscitation, pigs were randomized to receive 80,000 U/kg ulinastatin (n = 7) or the same volume of saline (n = 9) in the TCA group. Pigs in the sham group (n = 5) were not exposed to bleeding or cardiac arrest. At baseline and at 1, 3, and 6 h after the return of spontaneous circulation, blood samples were collected and assayed for tumor necrosis factor-alpha, interleukin 6, and other indicators of organ injury. At 24 h after resuscitation, pigs were sacrificed and apoptosis levels were assessed in samples of heart, brain, kidney, and intestine.

Results: One pig died in the ulinastatin group and one pig died in the TCA group; the remaining animals were included in the final analysis. TCA and resuscitation caused significant increases in multiple organ function biomarkers in serum, increases in tumor necrosis factor-alpha, and interleukin 6 in serum and increases in the extent of apoptosis in key organs. All these increases were lower in the ulinastatin group.

Conclusion: Ulinastatin may attenuate multiple organ injury after TCA, which should be explored in clinical studies.

Keywords: Ulinastatin, Traumatic cardiac arrest, Organ protection, Cardiopulmonary resuscitation, Post-resuscitation, Ischemia-reperfusion injury

Background

Traumatic cardiac arrest (TCA) is associated with poor outcome; traditionally, only 0–3.7% of TCA patients could be resuscitated [1], though advances in damage control resuscitation and understanding of TCA pathophysiology have increased the success rate to 5.6% (0–17%) [2], making it comparable to the rate with patients who suffer medical cardiac arrest [3].Guidelines of the National Association of EMS Physicians and the Committee on Trauma of the American College of Surgeons do not recommend resuscitation for patients who suffer blunt trauma and out-of-hospital cardiac arrest and found pulseless, without organized ECG activity, or for patients who have suffered penetrating trauma and have no detectable pulse and signs of life [4]. TCA is associated with greater loss of productive life years than medical cardiac arrest because TCA usually affects young men [3]. More than 90% of TCA cases are caused by severe head injury or hypovolemia [4]. Even among TCA patients who achieve a return of spontaneous circulation (ROSC), mortality rates are high because of the prolonged whole-body ischemia during trauma and cardiac arrest and because of reperfusion injury after resuscitation.

It may be possible to reduce TCA-induced damage using the urinary trypsin inhibitor (UTI) ulinastatin,
which was first identified in human blood and urine in the 1980s. Ulinastatin, which inhibits the release of neutrophil elastase and inhibits the activation of various pro-inflammatory cytokines [3, 5], is used mainly to treat pancreatitis, sepsis, toxic shock, and hemorrhagic shock [5, 6]. In animal models of brain ischemia-reperfusion, ulinastatin decreased infarct volume and water content of brain tissue, and it inhibited cerebral apoptosis, thereby mitigating ischemia-reperfusion injury [7, 8]. A meta-analysis of randomized controlled trials concluded that ulinastatin can protect pulmonary tissue for patients undergoing cardiac surgery and reduce postoperative inflammation [9]. In addition, ulinastatin may be associated with a low incidence of acute kidney injury in patients undergoing robot-assisted laparoscopic partial nephrectomy or cardiac surgery [10, 11].

Few studies have examined the efficacy and safety of ulinastatin in patients who have suffered cardiac arrest, particularly TCA. In the present study, we examined whether ulinastatin can mitigate the effects of TCA and ischemia-reperfusion based on serum indicators and extent of apoptosis in major organs in a porcine TCA model.

Methods
The experimental procedures used in this study adhered to the US National Institutes of Health Guide for the Care and Use of Laboratory Animals.

TCA
Twenty-one male Chinese pigs (29–36 kg) were used for this study. Anesthesia was induced using an intramuscular injection of ketamine (500 mg) and midazolam (5 mg) and maintained with propofol (3 mg/kg/h) and fentanyl (1 μg/kg/h) during surgical procedures. Respiration was maintained using artificial ventilation (SyrnVent E5; Mindray Biomedical Electronics, Shenzhen, China) with the following settings: respiratory rate, 12–15 bpm; inspired oxygen, 21% and PEEP, 3 mmHg. A catheter was inserted into the aortic artery through the left femoral artery and another catheter was inserted into the right atrium through the left jugular vein. Both catheters were connected to pressure transducers. Heart rate (HR), mean aortic blood pressure (MAP), and right atrial pressure (RAP) were monitored (Beneview T6; Mindray Biomedical Electronics, Shenzhen, China). The cannula in the right femoral artery was used for controlled blood-letting 40% of estimated blood volume at a constant rate during 20 min with a blood pump (JHB-2000B; JIHUA Medical Apparatus & Instruments, Guangzhou, China). Then, ventricular fibrillation was induced using a modified voltmeter (85 L1-A; Yongsheng Electric Instrument Co., Guangzhou, China). Respiration was suspended by separating the tracheal cannula from the ventilator. Artificial ventilation was resumed 5 min later, and pigs were defibrillated (Zoll Medical Corporation, USA) and manually resuscitated. Pigs that achieved ROSC were used in further interventions.

Experimental procedures
At 5 min after ROSC, pigs were infused with ulinastatin (80,000 U/kg; n = 6) or the same volume of normal saline (TCA group; n = 8) into the right femoral vein during 2 min. Half the blood withdrawn from the right femoral artery was reinfused through the right femoral vein during the first hour after ROSC. During the next 1-h period, pigs received a volume of normal saline equal to three times the volume of blood lost. As an additional control, sham pigs (n = 5) underwent surgery but were not subjected to bleeding, cardiac arrest or resuscitation.

Outcome measures
HR, MAP, RAP, and end-tidal carbon dioxide (ETCO₂) were recorded at baseline and at 1, 3, and 6 h after ROSC. Blood gases and coagulation function were also analyzed at these time points. Plasma samples stored at −80 °C were assayed for creatine kinase MB (CK-MB), cardiac troponin I (cTNI), neuron-specific enolase (NSE), S100 calcium-binding protein B (S100B), serum creatinin (sCr), blood urea nitrogen (BUN), intestinal fatty acid-binding protein (iFABP), diamine oxidase (DAO), IL-6, and TNF-α. Animals were sacrificed at 24 h after ROSC. Samples of the apical myocardium, frontal cortex of the brain, infrarenal pole cortex, and terminal ileum were removed and stored at −80 °C. Then, the samples were assessed for the extent of apoptosis using terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL), and they were analyzed for caspase-3 expression using immunohistochemistry.

Statistical analysis
Continuous data are presented as mean ± standard deviation (SD) and inter-group pairwise differences were analyzed using repeated measures one-way analysis of variance, followed by parametric Student’s t test. All statistical analyses were performed using SPSS for Windows 20.0 (IBM, Chicago, IL, USA), and statistical significance was defined as p < 0.05.

Results
Baseline characteristics
The three groups were similar at baseline in terms of body weight, HR, MAP, and, ETCO₂ (all p > 0.05; Table 1). One pig died in the ulinastatin group and one
in the TCA group. Additionally, all resuscitated animals survived to the end of the experiment.

Hemodynamics
After ROSC, HR was significantly higher in the TCA group than in the sham group \( (p < 0.05; \text{Fig. 1a}) \). HR was significantly lower in the ulinastatin group than in the TCA group \( (p < 0.05) \). MAP after ROSC did not differ significantly among the three groups \( (p > 0.05; \text{Fig. 1b}) \).

Serum biomarkers of myocardial injury
Prior to surgery, neither serum CKMB nor cTNI differed significantly among the three groups \( (all \ p > 0.05; \text{Fig. 1c, d}) \). CKMB increased from the pre-operative baseline and peaked at 1 h after ROSC in the ulinastatin group or at 3 h after ROSC in the TCA group. Similarly, cTNI increased from baseline and peaked at 3 h after ROSC in the ulinastatin group or at 6 h in the TCA group. Serum CK-MB and cTNI in the TCA group were significantly higher after ROSC than in the sham group \( (p < 0.01) \). CKMB after ROSC did not differ significantly between the TCA and ulinastatin groups \( (p > 0.05) \). The level of cTNI after ROSC was lower in the ulinastatin group than in the TCA group \( (p < 0.01) \).

Table 1 Baseline characteristics\(^a\)

| Characteristic | Sham \( (n = 5) \) | TCA \( (n = 9) \) | Ulinastatin \( (n = 7) \) | \( p^b \) |
|---------------|------------------|-----------------|------------------------|---------|
| Body weight (kg) | 35.00 ± 1.41 | 31.75 ± 3.99 | 31.67 ± 1.51 | 0.119 |
| Heart rate (bpm) | 86 ± 8 | 85 ± 15 | 85 ± 13 | 0.978 |
| ETCO\(_2\)/mmHg | 40 ± 2 | 39 ± 2 | 39 ± 2 | 0.623 |
| MAP (mmHg) | 117 ± 5 | 104 ± 16 | 106 ± 13 | 0.221 |
| Death/survival | 0/5 | 1/8 | 1/6 | 0.725 |

\( ^a \)mean ± SD. ETCO\(_2\) end-tidal carbon dioxide, MAP mean aortic blood pressure, TCA traumatic cardiac arrest

\( ^b \)There were no significant differences among the groups (one-way analysis of variance)

*Fig. 1 Hemodynamics and biomarkers of myocardial or cerebral injury among the three groups. a Heart rate (HR). b Mean aortic pressure (MAP). c Creatine kinase MB (CK-MB). d Cardiac troponin I (cTNI). e Neuron-specific enolase (NSE). f S100 calcium-binding protein B (S100B). The x-axis is the time point of baseline 1, 3, 6, and 24 h after ROSC. Values shown are mean ± SD. TCA, traumatic cardiac arrest; UTI, ulinastatin; BL, baseline; ROSC, return of spontaneous circulation. \(* p < 0.05, ** p < 0.01 \) vs. baseline; \(# p < 0.05, ## p < 0.01 \) vs. ulinastatin
Serum biomarkers of cerebral injury
Serum concentration of NSE and S100B did not differ among the three groups at baseline (all \( p > 0.05 \); Fig. 1e, f). Levels of both biomarkers were significantly higher after ROSC than at baseline in the TCA and ulinastatin groups (both \( p < 0.01 \)). Levels of both biomarkers after ROSC were higher in the TCA group than in the sham control (both \( p < 0.01 \)). The levels of both biomarkers after ROSC in the ulinastatin group were significantly lower than those in the TCA group (both \( p < 0.01 \)).

Serum biomarkers of renal injury
At baseline, sCr and BUN did not differ among the three groups (both \( p > 0.05 \); Fig. 2a, b). The level of sCr after ROSC was similar among the three groups (all \( p > 0.05 \)). BUN after ROSC was significantly higher in the ulinastatin group than at baseline (\( p < 0.01 \)), whereas BUN was similar between the ulinastatin and sham groups (\( p > 0.05 \)). BUN after ROSC was lower in the ulinastatin group than in the TCA group (\( p < 0.01 \)).

Serum biomarkers of intestinal injury
At baseline, serum concentrations of NSE and S100B did not differ among the three groups (all \( p > 0.05 \); Fig. 2c, d). After ROSC, the levels of iFABP and DAO were significantly higher in the TCA group than in the sham group (both \( p < 0.01 \)) and significantly lower in the ulinastatin group than in the TCA group (both \( p < 0.05 \)).

Arterial blood gas analysis
Baseline PaO\(_2\), SaO\(_2\), pH, and lactate concentration were not significantly different among the three groups (all \( p > 0.05 \); Additional file 1: Table S1). PaO\(_2\) and SaO\(_2\) of arterial blood after ROSC were higher in the ultralaminin group than in the TCA group (both \( p < 0.05 \)). The pH after ROSC was lower in the TCA group than in the sham group (\( p < 0.05 \)), and it tended to be higher in the ulinastatin group than in the TCA group, although the difference did not achieve statistical significance (\( p > 0.05 \)). Lactate after ROSC was significantly higher in the TCA group than in the sham group (\( p < 0.01 \)), while lactate was significantly lower in the ultralaminin group than in the TCA group (\( p < 0.05 \)).

Coagulation functions
Baseline PT, INR, APTT, and serum level of fibrinogen did not differ significantly among the three groups (all \( p > 0.05 \); Additional file 1: Table S2). PT, INR, and FIB after ROSC did not differ significantly among the three groups (all \( p > 0.05 \)). APTT was significantly higher in the ulinastatin group than in the TCA group (\( p < 0.05 \)), whereas it was similar between the TCA and sham groups (\( p > 0.05 \)).

Serum TNF-\(\alpha\) and IL-6
Preoperative TNF-\(\alpha\) and IL-6 did not differ significantly among the three groups (all \( p > 0.05 \); Fig. 3a, b). Serum TNF-\(\alpha\) and IL-6 in the TCA group were significantly higher after ROSC than in the sham group (both \( p < 0.01 \)). Serum TNF-\(\alpha\) and IL-6 were significantly lower higher than in the sham group (both \( p < 0.01 \)). Serum TNF-\(\alpha\) and IL-6 were significantly lower than in the sham group (both \( p < 0.01 \)).
after ROSC in ulinastatin group than in the TCA group (both $p < 0.01$).

**Histopathology of major organs**

The optical density of immunostaining against caspase-3 as well as the number of TUNEL-positive cells in the apical myocardium were significantly higher in the TCA group than in the sham group (both $p < 0.01$; Fig. 4a, b), while both of these parameters were lower in the ulinastatin group than in the TCA control (both $p < 0.05$).

The optical density of caspase-3 immunostaining in cerebral frontal tissue was significantly higher in the TCA group than in the sham group ($p < 0.01$; Fig. 5a, b), while it was significantly lower in the ulinastatin group than in the TCA group ($p < 0.01$). The same results were observed for the number of TUNEL-positive cells ($p < 0.05$ and $p < 0.01$, respectively).

The optical density of caspase-3 immunostaining and the number of TUNEL-positive cells in the renal cortex were significantly higher in the TCA group than in the sham group (both $p < 0.01$; Additional file 1: Table S3). Ulinastatin attenuated both measures of apoptosis (both $p < 0.01$ vs. TCA group).

The optical density of caspase-3 immunochrometry in terminal ileum was significantly higher in the TCA group than in the sham group ($p < 0.05$; Additional file 1: Table S3), whereas it was similar between the TCA and ulinastatin groups ($p > 0.05$). The number of TUNEL-positive cells was significantly higher in the TCA group than in the sham group ($p < 0.01$) and significantly lower in the ulinastatin group than in the TCA group ($p < 0.01$).

**Discussion**

The present study suggests that ulinastatin can improve hemodynamics and attenuate multiple organ injury following TCA in a porcine model. After ROSC, administration of ulinastatin suppressed the increase in HR and biomarkers of major organ injury. Ulinastatin was
associated with significantly higher PaO₂ and SaO₂ in arterial blood, as well as lower lactic acid, than in the TCA group. TCA in the present study was induced by controlled bleeding of 40% of total blood volume, followed by ventricular fibrillation. This model faithfully simulates the pathological causes of TCA in humans.

The main pathophysiological feature of TCA is ischemia-reperfusion injury [12], which is the main driver of morbidity and mortality in TCA patients. Ischemic damage occurs immediately during hemorrhage and cardiac arrest, whereas reperfusion injury occurs after ROSC. Such injury is associated with increases in oxygen free radicals and inflammatory factors, for example, superoxide anion free radical, hydrogen peroxide, hydroxyl radical, and TNF-α [7, 13–15]. In both animal studies and randomized clinical trials in humans, ulinastatin has shown protective effects against ischemia-reperfusion injury, leading to lower incidence of organ injury and higher survival rates [6, 9, 16–18]. How ulinastatin can mitigate ischemia-reperfusion injury remains unclear.

The present study showed that ulinastatin suppressed the increase in serum inflammatory factors after ROSC, consistent with previous studies of sepsis and septic shock [5, 6]. Inflammation plays an important role in ischemia-reperfusion injury and in apoptosis induction in multiple organs. Ulinastatin downregulates Toll-like receptors (TLRs) and NF-κB expression and protects the brain against ischemia-reperfusion injury [19]. TLRs form a complex with MyD88 to activate inflammatory cytokines and NF-κB, which regulates the expression of a wide array of genes involved in immune responses [19]. In the present study, we found that ulinastatin reduced TNF-α expression and IL-6 upregulation, consistent with previous studies [12, 20]. TNF-α can stimulate autophagy, and IL-13 suppresses autophagy by stimulating the phosphoinositide 3-kinase/mTOR signal transduction pathway [20]. In cell culture, ulinastatin may downregulates the autophagy marker LC3-II by improving cell viability in the face of hypoxia/deoxygenation [20]. Ulinastatin also reduces the upregulation of water transporter aquaporin 4 induced in heart and brain tissue in response to cerebral hemorrhage, cerebral trauma or cardiopulmonary resuscitation, and ulinastatin mitigating damage to cardiac arrest function by decreasing the expression of aquaporin 4 [21]. These various studies suggest that ulinastatin may help protect against ischemia injury by inhibiting proteases, inflammatory responses, and cytokine-dependent signaling pathways.

In the present study, the extent of myocardial injury was assessed based on CK-MB and C-TNI; the extent of intestinal injury, based on iFABP and DAO; and the extent of brain injury, NSE and S-100B, which are the most commonly used blood markers of such injury. Elevated NSE and S-100B are associated with poor outcome [22]. In the present study, ulinastatin attenuated tissue injury and cell apoptosis in the brain, heart, kidneys, and intestine. Ulinastatin appears to attenuate ischemia-reperfusion injury in multiple organs by suppressing inflammation and oxidative stress [7, 11, 23], which reduces the generation of oxygen free radicals that accompanies many pathological states such as inflammation, ischemia, and reperfusion [12]. Ischemia-reperfusion injury can cause endothelial barrier dysfunction, resulting in high vascular permeability and tissue edema, and ulinastatin has been shown to inhibit vascular hyperpermeability [24, 25]. Tissue edema reduces the supply of oxygen and nutrients, as well as the removal of waste products from tissues. The ischemia-reperfusion injury also triggers endothelial cell
inflammation that results in vascular dysfunction [8, 12]. Crystalloids have several disadvantages with respect to blood infusion: they improve circulation but cannot carry oxygen, they require the infusion of a greater volume of fluid, and they are associated with worse interstitial edema [4]. Ischemia-reperfusion injury induces endothelial production of vasoactive substances that cause vasoconstriction [12].

Factors that contribute to ischemia-reperfusion injury include energy metabolism, changes in the mitochondria and cellular membranes, initiation of different forms of cell death-like apoptosis, and necrosis [12, 26]. Energy metabolism depends on the delivery of blood and oxygen to the tissue, and it depends on the overall metabolic activity in the tissue. After ROSC, HR rises to increase stroke volume and maintain arterial blood pressure in order to compensate for hypovolemia. This increases ATP consumption and energy demand in the myocardium. In the present study, urokinase suppressed the increase in HR while maintaining aortic blood pressure. Ischemia-reperfusion initiates different forms of cell death-like apoptosis and necrosis, which recruits inflammatory cells to the necrotic areas and stimulates the release of cytokines [12]. Here, we showed that urokinase decreased apoptosis in major organs.

There are some limitations in the present study. First, cardiac arrest was induced by an electrode to produce ventricular fibrillation. However, ventricular arrhythmia occurs in < 3% of TCA patients, and 30–60% of patients present with pulseless electrical activity [4]. Second, urokinase in the present study was given at 80000 U/kg at 5 min after ROSC, but this regime may not be optimal for patients with TCA. Third, the observation period was only 24 h after ROSC, which is too short to capture the entire spectrum of post-cardiac arrest syndrome.

Conclusions

Urokinase can improve hemodynamics and attenuate multiple organ injury after TCA in a large animal model. Further clinical studies are needed.

Additional file

Additional file 1: Table S1. Blood gas analysis over time after ROSC in the TCA group (n = 8), urokinase group (n = 6) and sham group (n = 5). Table S2. Coagulation function over time after ROSC in the TCA group (n = 8), urokinase group (n = 6) and sham group (n = 5). Table S3. Caspase-3 levels and numbers of TUNEL-positive cells in the heart, cerebral, lung, renal, and intestinal tissues of the three groups. (DOCX 57 kb)

Abbreviations

BUN: Blood urea nitrogen; CK-MB: Creatine kinase MB; cTnI: Cardiac troponin I; DAO: Diamine oxidase; ETCO2: End-tidal carbon dioxide; HR: Heart rate; iFABP: Intestinal fatty acid-binding protein; IL: Interleukin; MAP: Mean aortic blood pressure; NSE: Neuron-specific enolase; RAP: Right atrial pressure; ROSC: Return of spontaneous circulation; S100B: S100 calcium-binding protein B; sCr: Serum creatinine; SD: Standard deviation; TCA: Traumatic cardiac arrest; TNF: Tumor necrosis factor; TUNEL: Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling; UTI: Urinary trypsin inhibitor

Acknowledgements

We thank Moli Li for assistance with animal preparation.

Ethical approval and consent to participate

This study was conducted in accordance with the requirements indicated in the guidelines of Institutional Animal Care and Use Committees, after the approval from the Ethics Committee of the Second Affiliated Hospital of Zhejiang University School of Medicine (approval number: IACUC-P20170702).

Funding

Mao Zhang is funded by the Welfare Scientific Research Project from the Chinese Ministry of Health (2015SSQ00050), the Key Program Co-sponsored by Zhejiang Province and National Health and Family Planning Commission of China (2018271879), and the Welfare Scientific Research Project of Zhejiang Province (LGF18H150003). These agencies provided financial support but were not involved in any other aspect of the research.

Availability of data and materials

All the data are available and will be submitted if required.

Authors’ contributions

ZM (corresponding author) was in charge of the study design and data analysis. LS (first author) was responsible for the data analysis and manuscript writing and cooperated with XJ, GY, SP, and SX in animal research work. All authors participated in the critical revision of the manuscript, and all authors approved the final version to be submitted.

Consent for publication

Not applicable

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

1Department of Emergency Medicine, Second Affiliated Hospital, Zhejiang University School of Medicine, No. 88 Jiefang road, Hangzhou 310009, China. 2Institute of Emergency Medicine, Zhejiang University, No. 88 Jiefang road, Hangzhou 310009, China. 3Department of Emergency Medicine, Yuyao People’s Hospital, Medical School of Ningbo University, Yuyao 315400, China. 4Department of Emergency Medicine, The First Hospital of Jiaxing/The First Affiliated Hospital of Jiaxing University, Jiaxing 314000, China. 5Department of Emergency Medicine, Huazhou Central Hospital, Huazhou 313000, China.

Received: 6 August 2018 Accepted: 18 October 2018

References

1. Lockey D, Crewdson K, Davies G. Traumatic cardiac arrest: who are the survivors? Ann Emerg Med. 2006;48:240–4.
2. Harris T, Masud S, Lamond A, Abu-Habsa M. Traumatic cardiac arrest: a unique approach. Eur J Emerg Med. 2015;22:72–8.
3. Smith JE, Rickard A, Wise D. Traumatic cardiac arrest. J R Soc Med. 2015;108:11–6.
4. Hopson LR, Hirsh E, Delgado J, Domeier RM, McSwain NE, Krohmer J, et al. Guidelines for withholding or termination of resuscitation in prehospital traumatic cardiopulmonary arrest: joint position statement of the National Association of EMS Physicians and the American College of Surgeons Committee on Trauma. J Am Coll Surg. 2003;196:106–12.
5. Feng Z, Shi Q, Fan Y, Wang Q, Yin W. Urokinase and/or thymosin α1 for severe sepsis: a systematic review and meta-analysis. J Trauma Acute Care Surg. 2016;80:335–40.
6. Karnad DR, Bhadade R, Verma PK, Moulick ND, Daga MK, Chafekar ND, et al. Intravenous administration of ulinastatin (human urinary trypsin inhibitor) in severe sepsis: a multicenter randomized controlled study. Intensive Care Med. 2014;40:830–8.

7. Chen HM, Huang HS, Ruan L, He YB, Li XJ. Ulinastatin attenuates cerebral ischemia-reperfusion injury in rats. Int J Clin Exp Med. 2014;7:1483–9.

8. Liu M, Shen J, Zou Y, Zhao Y, Li B, Fan M. Effect of ulinastatin on the permeability of the blood-brain barrier on rats with global cerebral ischemia/reperfusion injury as assessed by MRI. Biomed Pharmacother. 2017;85:412–7.

9. He QL, Zhong F, Ye F, Wei M, Liu WF, Li MN, et al. Does intraoperative ulinastatin improve postoperative clinical outcomes in patients undergoing cardiac surgery: a meta-analysis of randomized controlled trials. Biomed Res Int. 2014;2014:630835.

10. Lee B, Lee SY, Kim NY, Rha KH, Choi YD, Park S, et al. Effect of ulinastatin on postoperative renal function in patients undergoing robot-assisted laparoscopic partial nephrectomy: a randomized trial. Surg Endosc. 2017;31:3728–26.

11. Wan X, Xie X, Gendoo Y, Chen C, Ji X, Cao C. Ulinastatin administration is associated with a lower incidence of acute kidney injury after cardiac surgery: a propensity score matched study. Crit Care. 2016;20:42.

12. Salvador M, Rosso G, Bertoni E. Update on ischemia-reperfusion injury in kidney transplantation: pathogenesis and treatment. World J Transplant. 2015;5:52–67.

13. Korthuis RJ, Granger DN, Townsley MI, Taylor AE. The role of oxygen-derived free radicals in ischemia-induced increases in canine skeletal muscle vascular permeability. Circ Res. 1985;57:599–609.

14. Werns SW, Shea MJ, Driscoll EM, Cohen C, Abrams GD, Pitt B, et al. The independent effects of oxygen radical scavengers on canine infarct size. Reduction by superoxide dismutase but not catalase. Circ Res. 1985;56:895–8.

15. Baker GL, Cory RJ, Autor AP. Oxygen free radical induced damage in kidneys subjected to warm ischemia and reperfusion. Protective effect of superoxide dismutase Ann Surg. 1985;202:628–41.

16. Lili X, Zhiyong H, Jianjun S. A preliminary study of the effects of ulinastatin on early postoperative cognition function in patients undergoing abdominal surgery. Neurosci Lett. 2013;541:15–9.

17. Lv ZT, Huang JM, Zhang JM, Zhang JM, Guo JF, Chen AM. Effect of ulinastatin in the treatment of postoperative cognitive dysfunction: review of current literature. Biomed Res Int. 2016;2016:2571080.

18. Inoue K, Takano H. Urinary trypsin inhibitor as a therapeutic option for endotoxin-related inflammatory disorders. Expert Opin Investig Drugs. 2010;19:513–20.

19. Li X, Su L, Zhang X, Zhang C, Wang L, Li Y, et al. Ulinastatin downregulates TLR4 and NF-κB expression and protects mouse brains against ischemia/reperfusion injury. Neurol Res. 2017;39:637–73.

20. Xiao J, Zhu X, Ji G, Yang Q, Kang B, Zhao J, et al. Ulinastatin protects cardiomyocytes against ischemia-reperfusion injury by regulating autophagy through mTOR activation. Mol Med Rep. 2014;10:1949–53.

21. He W, Liu Y, Geng H, Li Y. The regulation effect of ulinastatin on the expression of SSAT2 and AQP4 in myocardial tissue of rats after cardiopulmonary resuscitation. Int J Clin Exp Pathol. 2015;8:10792–9.

22. Callaway CW, Donnino MW, Fink EL, Geocadin RG, Golan E, Kern KB, et al. Part B: post-cardiac arrest care. 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2015;132:5465–582.

23. Guan L, Liu H, Fu P, Li Z, Li P, Xie L, et al. The protective effects of trypsin inhibitor on hepatic ischemia-reperfusion injury and liver graft survival. Oxidative Med Cell Longev. 2016;2016:1429835.

24. Ma L, Zhang H, Liu YZ, Yin YL, Ma YQ, Zhang SS. Ulinastatin decreases permeability of blood–brain barrier by inhibiting expression of MMP-9 and t-PA in postoperative aged rats. Int J Neurosci. 2016;126:463–8.

25. Lin B, Liu Y, Li T, Zeng K, Cai S, Zeng Z, et al. Ulinastatin mediates protection against vascular hyperpermeability following hemorrhagic shock. Int J Clin Exp Pathol. 2015;8:7685–93.

26. Cho YS, Shin MS, Ko IG, Kim SE, Kim CJ, Sung YH, et al. Ulinastatin inhibits cerebral ischemia-induced apoptosis in the hippocampus of gerbils. Mol Med Rep. 2015;12:1796–802.